Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease Dementia

Movement Disorders

Volumn 24, Issue 7, 2009, Pages 1028-1033

  Zoccolella, Stefano ^a   dell'Aquila, Claudia ^b   Abruzzese, Giovanni ^c   Antonini, Angelo ^d   Bonuccelli, Ubaldo ^e   Canesi, Margherita ^d   Cristina, Silvano ^f   Marchese, Roberta ^c   Pacchetti, Claudio ^f   Zagaglia, Roberto ^f   Logroscino, Giancarlo ^b   Defazio, Giovanni ^b   Lamberti, Paolo ^b   Livera, Paolo ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d PARKINSON INSTITUTE   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Dementia; Folate; Homocysteine; Parkinson's disease; Progression

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; LOGISTIC MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 67651171530     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22511     Document Type: Article

References (38)

1. Chaudhuri KR, Healy DG, Schapira AH. National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
2. Caballo N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007;22(S17):S358-S366.
3. Hely MA, Reid WG, Halliday GM, Morris JG. The sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
4. Louis ED, Marder K, Cote L, Tang M, Mayeux RL. Mortality from Parkinson's disease. Arch Neurol 1997;54:260-264.
5. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population based, prospective study. J Am Geriatr Soc 2000;48:938-942.
6. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
7. Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004;80:114-122.
8. Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a risk factor for dementia and Alzheimer's Disease. N Engl J Med 2002;346:476-483.
9. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003;2:425-428.
10. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126: 170-175.
11. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003;26:137-146.
12. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate de.ciency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997;8:634-640.
13. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levo-dopa and COMT Inhibitors on plasma Homocysteine in PD patients. Mov Disord 2005;20:69-72.
14. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Park Relat Disord 2005;11:131-133.
15. O'Suilleabhain PE, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004;61:633-634.
16. O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868.
17. Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005;43:1107-1110.
18. O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB, Jr, Bottiglieri T, Diaz-Arrastia R. Clinical course in Parkinson's disease with elevated homocysteine. Park Relat Disord 2006;12:103-107.
19. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intimamedia thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29:305-311.
20. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
21. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
22. Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA homocystein (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41: 1392-1403.
23. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
24. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Liebermann A, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-163.
25. Folstein MF, Folstein FE, Mc Hugh POR. Mini-mental state: a practical method for grading the cognitive state for the clinician. J Psychiatr Res 1975;12:189-198.
26. Appollonio I, Leone M, Isella V, et al. The frontal assessment battery (FAB): normative values in an Italian population sample. Neurol Sci 2005;26:108-116.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th ed. Washington, DC: American Psychiatric Association; 2000.
28. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
29. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-446.
30. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nat Genet 1995;10:111-113.
31. Yip AG, Brayne C, Matthews FE,MRC Cognitive Function and Ageing Study Group. Risk factors for incident dementia in England and Wales: the medical research council cognitive function and ageing study. A population-based nested case-control study. Age Ageing 2006;35:154-160.
32. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002;51:722-729.
33. Aarsland D, Kvaløy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007;254:38-45.
34. Qureshi GA, Qureshi AA, Devrajani BR, Chippa MA, Syed SA. Is the de.ciency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson's patients? CNS Neurol Disord Drug Targets 2008;7:20-27.
35. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol 2002;51:285-289.
36. Vermeer SE, Prins ND, den Hejer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
37. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F. Homocysteine and Parkinson's disease: a dangerous liaison? J Neurol Sci 2007;257:31-37.
38. Clarke R, Woodhouse P, Ulvik A, et al. Variability and determinants of homocysteine concentrations in plasma in an elderly population. Clin Chem 1998;44:102-107.